MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Halozyme Therapeutics Inc

Gesloten

SectorGezondheidszorg

62.97 1.88

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

61.38

Max

63.06

Belangrijke statistieken

By Trading Economics

Inkomsten

1K

137M

Verkoop

7.9M

298M

K/W

Sectorgemiddelde

18.604

63.778

EPS

1.26

Winstmarge

45.976

Werknemers

350

EBITDA

13M

203M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+7.11% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

690M

7.9B

Vorige openingsprijs

61.09

Vorige sluitingsprijs

62.97

Nieuwssentiment

By Acuity

50%

50%

180 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Halozyme Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 mrt 2025, 19:42 UTC

Top Nieuws

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5 mrt 2025, 10:30 UTC

Top Nieuws

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

1 nov 2024, 11:30 UTC

Top Nieuws

S&P 500 Futures Climb In Premarket Trading; Atlassian, XP Lead

Peer Vergelijking

Prijswijziging

Halozyme Therapeutics Inc Prognose

Koersdoel

By TipRanks

7.11% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 67.5 USD  7.11%

Hoogste 78 USD

Laagste 53 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Halozyme Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

8 ratings

5

Buy

3

Hold

0

Sell

Technische score

By Trading Central

62.85 / 63.8825Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

180 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.